Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 21, 2022, Kura Oncology, Inc. held its Annual Meeting of Stockholders (the "Annual Meeting"). As of the close of business on April 25, 2022, the record date for the Annual Meeting, there were 66,636,105 shares of common stock outstanding, of which 59,343,019 shares of common stock were present in person or represented by proxy at the Annual Meeting.

At the Annual Meeting, stockholders:

(1) elected Helen Collins, M.D., Thomas Malley and Carol Schafer as Class II directors to hold office until the 2025 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or removal;

(2) ratified the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022; and

(3) approved, on an advisory basis, the compensation paid to our named executive officers as disclosed in the proxy statement.

The following sets forth detailed information regarding the final results of the voting for the Annual Meeting:

Proposal 1. Election of Directors



Name of Director Elected       For            Withheld        Broker Non-Votes
Helen Collins, M.D.          57,064,038         41,907             2,237,074
Thomas Malley                45,291,528       11,814,417           2,237,074
Carol Schafer                55,357,978       1,747,967            2,237,074


Proposal 2. Ratification of the Selection of Independent Registered Public
Accounting Firm

    For          Against      Abstain      Broker Non-Votes
  59,316,262        5,210       21,547                 -

Proposal 3. Advisory Vote on Executive Compensation



    For            Against       Abstain       Broker Non-Votes
  54,865,869       2,211,677       28,399           2,237,074




--------------------------------------------------------------------------------

© Edgar Online, source Glimpses